Roland Schott

Strasbourg, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 68 publications

Treatment patterns and outcomes in advanced and metastatic lung cancer in France: Results from the Epidemiological Strategy and medical Economics (ESME) database lung cancer in France.

Treatment patterns and outcomes in advanced and metastatic lung cancer in France: Results from the Epidemiological Strategy and medical Economics (ESME) database lung cancer in France.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 16, 2026

NF-κB signaling drives rapid skeletal muscle atrophy in patients with breast cancer: the cost of fighting cancer with chemotherapy.

NF-κB signaling drives rapid skeletal muscle atrophy in patients with breast cancer: the cost of fighting cancer with chemotherapy.

Journal: American journal of physiology. Cell physiology

Published: April 16, 2026

Impairments in mitochondrial dynamics and morphology in skeletal muscle of breast cancer patients after a single paclitaxel administration.

Impairments in mitochondrial dynamics and morphology in skeletal muscle of breast cancer patients after a single paclitaxel administration.

Journal: Experimental physiology

Published: April 09, 2026

From relapse to survival: real-world clinical impact of a multimodal approach in first-time recurrent glioblastoma : FROST: multimodal treatment for GBM recurrence.

From relapse to survival: real-world clinical impact of a multimodal approach in first-time recurrent glioblastoma : FROST: multimodal treatment for GBM recurrence.

Journal: Journal of neuro-oncology

Published: March 20, 2026

Innovative Dose-Response Assessment of the Metaboreflex With Indirect Control of Intramuscular Metabolic Perturbation in Humans.

Innovative Dose-Response Assessment of the Metaboreflex With Indirect Control of Intramuscular Metabolic Perturbation in Humans.

Journal: Acta physiologica (Oxford, England)

Published: January 26, 2026

Prolonged complete metabolic response to chemotherapy combined with amivantamab with high grade cutaneous toxicity after osimertinib resistance in an uncommon T751_I759delinsAsp EGFR-mutant lung adenocarcinoma: a case report.

Prolonged complete metabolic response to chemotherapy combined with amivantamab with high grade cutaneous toxicity after osimertinib resistance in an uncommon T751_I759delinsAsp EGFR-mutant lung adenocarcinoma: a case report.

Journal: Translational lung cancer research

Published: October 28, 2025

Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review.

Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review.

Journal: Current oncology (Toronto, Ont.)

Published: October 15, 2025

Feasibility and Potential Effects of Exercise Training Combining Eccentric and Concentric Cycling in Patients With Breast Cancer.

Feasibility and Potential Effects of Exercise Training Combining Eccentric and Concentric Cycling in Patients With Breast Cancer.

Journal: European journal of sport science

Published: October 09, 2025

Real-world survival and prognostic factors in WHO 2021 classified gliomas treated with chemo-radiotherapy.

Real-world survival and prognostic factors in WHO 2021 classified gliomas treated with chemo-radiotherapy.

Journal: Scientific reports

Published: June 29, 2025

EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer.

EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 12, 2025

Prediction of survival and outcomes with depth of response at 6 months in metastatic non-small-cell lung cancer patients treated with chemotherapy and immunotherapy combination: SPORE trial.

Prediction of survival and outcomes with depth of response at 6 months in metastatic non-small-cell lung cancer patients treated with chemotherapy and immunotherapy combination: SPORE trial.

Journal: ESMO open

Published: February 04, 2025

Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study.

Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study.

Journal: Targeted oncology

Published: February 03, 2025

Showing 1-12 of 68

Last Updated: 09/26/2026